

Investora 2020

Cicor Technologies Ltd.

September 24, 2020

Cicor Technologies Ltd. **Alexander Hagemann** CEO

Patric Schoch CFO Bloom Diagnostics AG **Dr. med. Angelica Kohlmann**Co-founder & Executive Chairman



Disclaimer

September 24, 2020


The information in this presentation does not constitute an offer or invitation and may not be construed as a recommendation by us to purchase, hold or sell shares of Cicor Technologies Ltd. This information or any copy thereof may not be sent or taken to or distributed in any jurisdiction in which such transmission or distribution is unlawful. This document may contain certain 'forward-looking' statements. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances. Actual outcomes and results may differ materially from any outcomes or results expressed or implied by such forward-looking statements.



The Cicor Group

Your technology partner

- Swiss leader in design and manufacturing of advanced electronics
- Pioneering microelectronics since 1966 listed at SIX Swiss Exchange in 1998
- Focus on high value applications: Medical, industrial, aerospace & defence
- 2019 net sales of CHF 254 million, 9.8% EBITDA margin





Leading technologies for advanced electronics

An unparalleled offering of products and services

AMS Division



ES Division






Advanced Microelectronics and Substrates

The strongest platform in the industry for high precision electronic substrates and microelectronics:

- Thin-film and thick-film substrates
- High density printed circuit boards (PCB)
- Microelectronic packaging and assembly

Share of Sales




EBITDA Margin **16.7%**

Electronic Solutions

Realization of advanced electronic devices along the product lifecycle:

- Engineering from concept to mass production
- Assembly services
- Printed electronics
- High precision plastic injection molding and toolmaking

Share of Sales




EBITDA Margin **6.5%**

All numbers are H1/2020



Global footprint

High tech and competitiveness – close to the customer






Cicor in H1/2020

Financials reflect resilience in the challenging COVID-19 environment


- Net sales of CHF 109 million (minus 17.3% to PY, in local currencies minus 13.6%)
- EBITDA margin of 8.5% (PY: 9.0%)
- New orders of CHF 92.6 million (minus 17.2%) starting to recover in Q3
- Medical sales almost flat in local currencies; steep decline in watches & consumer, automotive & transport





Record high new business pipeline

- Highest ever volume of quoted new projects
- Cicor USP well recognized by OEM for high-end electronics
- Trade tensions and COVID-19 pandemic are driving Nearshoring and China+1 strategies in the electronics industry
- Competitor consolidation through attrition








Alexander Hagemann

Strong position in an attractive market




Strong position in an attractive market

Introduction












Operating in a growth market

Electronic Manufacturing Services (EMS) industry revenues with 14% CAGR since 1990



«The electronics supercycle is driven by demand for the connection of everything.»


«The resilience of the industry, diverse customer base, ... and the electronics supercycle are driving long term growth in the EMS industry.»

Source: Lincoln International, June 2020




Focus on attractive applications

A.I.M. - Segments with highest margins and customer loyalty due to quality requirements and innovation









Winning market share

Increasing market share in A.I.M. target sectors



Cicor's unique selling propositions (USP):

Design excellence

More than 150 engineers for HW/SW development, product- and process engineering, project management

Technology leadership

PCB, Thin-film, Microelectronics, Electronic printing, ...

Global network

- 5 high tech sites in Switzerland, Germany
- 5 low cost sites in Romania, Southeast Asia, China

All numbers normalized in USD

Sources: New Venture Research, Cicor



Leading position in the D-A-CH region

As top 3 player in the relevant market, Cicor has a strong foundation for further growth



Sources: New Venture Research, Cicor. Ranking by 2019 revenue in A.I.M. markets

Regional leadership

- Customers are «hidden champions» and innovation leaders in D-A-CH
- Close communication between partners
- Aiming for No. 2 in D-A-CH in A.I.M. markets
- 2ollner Elektronik AG, Germany (\$ 1.040 million)
- 2 Katek SE, Germany (\$ 230 million)
- Cicor Technologies Ltd., Switzerland (\$ 200 million)
- BMK Group GmbH & Co. KG, Germany (\$ 170 million)
- TQ-Systems GmbH, Germany (\$ 160 million)






Patric Schoch

Financial Results H1/2020



Financial achievements H1/2020

All figures in CHF million at actual FX rates



Sales decline of -13.6% in local currencies



Successful financial management to secure results in H1/2020

Four important topics under special focus during the first semester

Strong cost discipline: Actively managing and monitoring company spend in H1 helped to secure the company results.

Being profitable:

Net profit of CHF 1.7 million achieved despite 17% lower net sales vs. H1/19 and against all the adversity faced in the first semester.

3 Securing the cash flow: Without a high demand on capex and with a stable NWC position, Cicor generated a positive free cash flow of CHF 0.7 million

With the strict focus on cash and cost, net debt was kept around under full control:

CHF 20 million (Net debt / EBITDA ratio < 1), even with distributing CHF 4.3 million in dividends to the shareholders in April 2020.





Alexander Hagemann

Case study – partnering with innovation leaders



Value proposition

Swiss Quality

Cicor Group

- Engineering and consulting
- Life cycle services



- Industry 4.0 assembly
- Microelectronics
- High precision substrates
- Micro molding
- Electronic printing







Bloom Diagnostics AG – Cicor Technologies Ltd.



Bloom Diagnostics AG – Cicor Technologies Ltd.

2018 Bloom, a health tech startup, engages with Cicor as CDMO:

- 1st stage: Development of a "mini-lab" (or reader) to quantify results of rapid blood-test (or other bodily fluids), including electronic boards, hardware and firmware, compatible with Bluetooth and with Bloom's proprietary software targeting rel. low product costs.
- 2nd stage: Prepare production aligned with all QM and Regulatory requirements for both, Europe and the US.
- 3rd stage: Ramp up and go to market.

Presently, we are successfully finalizing stage 3. Regulatory approvals all granted.



The Bloom Lab analyzes Bloom Test strips in a few minutes



Bloom Diagnostics

Zurich

Vienna

New York

www.bloomdiagnostics.com





Alexander Hagemann

Outlook and targets



Outlook

Expectations for 2020



- Assuming there will be no further lockdown in our customer's markets,
 Cicor expects a recovery of the business from Q4/2020 onwards
- Cicor provides the following guidance for the full year of 2020, assuming a stable currency situation compared to H1/2020:
 - Net Sales: 15% to 20 % below 2019
 - EBIT margin: 3% to 4%
- Due to the record-high pipeline of new projects, further market share gains can be expected in the coming years
- Cicor is in a much stronger financial and operational position than many competitors and should therefore emerge from the crisis as a winner



Mid-term targets

Cicor Technologies Ltd.

Market Focus

Medical Industrial Aerospace Topline growth

Above the growth of global electronics production

EBIT target

6 - 8%

Profit distribution

Stable and increasing Dividends



Investor Relations

Contacts



Alexander Hagemann CEO

Cicor Management AG
Gebenloostrasse 15
CH - 9552 Bronschhofen
investor@cicor.com
+41 71 913 73 00



Patric Schoch CFO



Michael GöttiVP Corporate Marketing & Communications





Thank you for your attention

www.cicor.com/investors



